|

Feasibility of a Preoperative, Multimodal Lifestyle Intervention in Patients With Breastcancer

RECRUITINGN/ASponsored by Maastricht University Medical Center
Actively Recruiting
PhaseN/A
SponsorMaastricht University Medical Center
Started2024-05-27
Est. completion2025-11-01
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

The primary objective of this study is to investigate the feasibility of a multimodal prehabilitation programme consisting of MIET during neoadjuvant intravenous chemotherapy infusion, HITT and strength training during the last six weeks prior to surgery, and optimising nutritional intake throughout the total preoperative period in patients with breast cancer with respect to recruitment, adherence, dropout, safety and acceptance. The secondary objective is to provide a preliminary evaluation of participant responses to a preoperative multimodal lifestyle intervention, on cardiorespiratory fitness, muscle strength, nutritional status, and fatigue in patients with breast cancer receiving neoadjuvant chemotherapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients diagnosed with stage I-III breast cancer eligible for neoadjuvant intravenous chemotherapy at the MUMC+
* Aged ≥18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale grade 0-1 (Table 1)
* Enough understanding of the Dutch language

Exclusion Criteria:

* Human Epidermal growth factor Receptor 2 (HER2) - positive tumour
* Scalp cooling
* Conditions that seriously hamper physical exercise
* Incapacitated subjects as reported by the attending medical specialist in the medical record. When any doubt arises, the patient will not be considered eligible.

Conditions3

Breast CancerBreast NeoplasmsCancer

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.